#United States #San Antonio #Breast Cancer #SystImmune #BL-B01D1

SystImmune's Presentation of Updated BL-B01D1 Data at SABCS 2024

SystImmune, Inc., a biotechnology firm focused on developing new cancer therapies, announced it will present vital data on its investigational drug, BL-B01D1, at the San Antonio Breast Cancer Symposium (SABCS) 2024, held from December 10 to 13.

Overview of BL-B01D1

BL-B01D1 is a bispecific antibody-drug conjugate (ADC) that targets both the EGFR and HER3 proteins, which are commonly overexpressed in multiple types of epithelial tumors. This collaboration between SystImmune and Bristol Myers Squibb is noteworthy because the drug is positioned potentially to be a first-in-class therapeutic option for breast cancer.

The results to be disclosed at the symposium will come from a Phase 1 clinical study that included a diverse patient population, comprising individuals diagnosed with advanced triple-negative, HR-positive/HER2-negative, and HER2-positive breast cancer. These data further substantiate the ongoing development of BL-B01D1 and continue to build on previous findings involving patients with lung and bladder cancers.

Promising Research Developments

According to Dr. Jonathan Cheng, the Chief Medical Officer of SystImmune, the forthcoming results significantly contribute to the existing body of evidence supporting the drug’s efficacy across major subtypes of breast cancer. He expressed optimism regarding the manageable safety profile of BL-B01D1 and emphasized SystImmune's dedication to advancing clinical trials, both as a standalone treatment and in combination with other therapeutic agents. This approach aims to enhance treatment outcomes for women battling breast cancer globally.

The specifics of the presentation include information on BL-B01D1’s updated results in patients with locally advanced or metastatic breast cancer.

Presentation Details

• - Presentation Title: BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Locally Advanced or Metastatic Breast Cancer and other Solid Tumors
• - Presentation Number: P5-07-27/Abstract SESS-630
• - Speaker: Dr. Jiong Wu
• - Onsite Poster Display Date: Friday, December 13, 2024

SystImmune’s Commitment to Innovation

SystImmune operates out of Redmond, WA, focusing on the advancement of groundbreaking cancer treatments through innovative drug development strategies. Their seasoned experience in bi-specific and multi-specific antibodies, along with antibody-drug conjugates, places them at the forefront of cancer research and therapeutics.

In addition to the development of BL-B01D1, SystImmune is making strides with its diverse pipeline of therapeutics in various clinical stages, giving hope to patients with challenging cancers.

Despite exciting advancements, SystImmune emphasizes that the reliable application of this information does not replace personalized medical advice. Patients with specific health concerns are encouraged to consult their healthcare professionals for suitable treatment plans.

Conclusion

The upcoming SABCS 2024 promises to be a significant event for SystImmune as they unveil their latest findings with BL-B01D1. As the clinical landscape evolves, the need for collaborative innovation in cancer therapy remains paramount, and SystImmune continues to contribute to this necessary endeavor.